ArticleBioconjugate chemistry2013
Cellular uptake and cytotoxicity of drug-peptide conjugates regulated by conjugation site.
Article in Bioconjugate chemistry, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed.
- Cell-Penetrating Peptides and Supercharged Proteins: A Comprehensive Protocol from Isolation to Cellular Uptake.Molecular pharmaceutics · 2026Article
- Synthesis and Characterization of Polymer-Drug Conjugates by Strain-Promoted Azide-Alkyne Cycloaddition-Mediated Polymerization.Journal of applied polymer science · 2025Article
- Gemcitabine-Doxorubicin Combination Polymer-Drug Conjugate Prepared by SPAAC Click Chemistry: In Vitro Characterization.International journal of molecular sciences · 2025Article
- Drug conjugates for the treatment of lung cancer: from drug discovery to clinical practice.Experimental hematology & oncology · 2024Review
- Targeted Glioma Therapy-Clinical Trials and Future Directions.Pharmaceutics · 2024Review
- Research advances in peptide‒drug conjugates.Acta pharmaceutica Sinica. B · 2023Review
- Biopolymer-Based Nanogel Approach in Drug Delivery: Basic Concept and Current Developments.Pharmaceutics · 2023Review
- A Novel Homodimer Peptide-Drug Conjugate Improves the Efficacy of HER2-Positive Breast Cancer Therapy.International journal of molecular sciences · 2023Article
- Peptide Drug Conjugates and Their Role in Cancer Therapy.International journal of molecular sciences · 2023Review
- Enzyme-Responsive Amphiphilic Peptide Nanoparticles for Biocompatible and Efficient Drug Delivery.Pharmaceutics · 2022Article
- Cell-penetrating peptides improve pharmacokinetics and pharmacodynamics of anticancer drugs.Tissue barriers · 2022Review
- Supramolecular Nanomedicines ofFrontiers in chemistry · 2022Review
- Cell-Penetrating Peptides: Applications in Tumor Diagnosis and Therapeutics.Pharmaceutics · 2021Review
- The Interaction of Supramolecular Anticancer Drug Amphiphiles with Phospholipid Membranes.Nanoscale advances · 2021Article
- ConjuPepDB: a database of peptide-drug conjugates.Nucleic acids research · 2021Article
- Protein-Based Nanohydrogels for Bioactive Delivery.Frontiers in chemistry · 2021Review
- Polymer-drug conjugate therapeutics: advances, insights and prospects.Nature reviews. Drug discovery · 2019Review
- Recent Advances in Cell Penetrating Peptide-Based Anticancer Therapies.Molecules (Basel, Switzerland) · 2019Review
- A Novel Peptide Interfering with proBDNF-Sortilin Interaction Alleviates Chronic Inflammatory Pain.Theranostics · 2019Article
- Membrane Active Peptides and Their Biophysical Characterization.Biomolecules · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Conjugation of anticancer drugs to hydrophilic peptides such as Tat is a widely adopted strategy to improve the drug's solubility, cellular uptake, and potency against cancerous cells. Here we report that attachment of an anticancer drug doxorubicin to the N- or C-terminal of the Tat peptide can have a significant impact on their cellular uptake and cytotoxicity against both drug-sensitive and drug-resistant cancer cells. We observed higher cellular uptake by both cell lines for C-terminal conjugate relative to the N-terminal analogue. Our results reveal that the C-terminal conjugate partially overcame the multidrug resistance of cervical cancer cells, while the N-terminal conjugate showed no significant improvement in cytotoxicity when compared with free doxorubicin. We also found that both N- and C-conjugates offer a mechanism to circumvent drug efflux associated with multidrug resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.